Key Treatment in Lilly Portfolio Hits Shelves

Lilly says more than 246

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

A new treatment co-developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is now available at U.S. pharmacies. Synjardy, which was launched in partnership with Boehringer Ingelheim Pharmaceuticals Inc., is a combination tablet that treats patients with type 2 diabetes.

Boehringer Ingelheim Vice President of Clinical Development and Medical Affairs – Metabolism Thomas Seck "Boehringer Ingelheim and Lilly are committed to helping improve care for adults with type 2 diabetes. As part of that effort, we are proud to make Synjardy, the third product from our diabetes alliance containing Jardiance, available to patients soon after its FDA approval."

The U.S. Food and Drug Administration approved SYNJARDY a month-and-a-half ago.

You can find out more information about the treatment by clicking here.